Back to Search
Start Over
Safety and efficacy of baclofen in the treatment of alcohol-dependent patients.
- Source :
-
Current pharmaceutical design [Curr Pharm Des] 2010; Vol. 16 (19), pp. 2113-7. - Publication Year :
- 2010
-
Abstract
- Preclinical studies show that antagonism of the GABA(B) receptor may represent an effective neuropharmacological approach to treat alcohol dependence. Consistent with preclinical evidence, the majority of the human studies have demonstrated that the prototype GABA(B) receptor antagonist baclofen may represent an effective mediation to treat alcohol-dependent individuals. Specifically, baclofen has shown to reduce alcohol withdrawal symptoms, as well as to reduce alcohol craving and intake, and to promote alcohol abstinence. Notably, baclofen has shown a safe profile when administered to alcoholics, including those with liver cirrhosis. In summary, baclofen represents a safe and effective medication to treat alcohol dependence, thus holding promise as a new pharmacotherapy. However, large studies are needed to confirm the present findings.
- Subjects :
- Alcohol Drinking prevention & control
Alcoholism physiopathology
Animals
Baclofen adverse effects
Baclofen pharmacology
GABA Agonists adverse effects
GABA Agonists pharmacology
GABA-B Receptor Agonists
Humans
Receptors, GABA-B metabolism
Substance Withdrawal Syndrome drug therapy
Alcoholism drug therapy
Baclofen therapeutic use
GABA Agonists therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1873-4286
- Volume :
- 16
- Issue :
- 19
- Database :
- MEDLINE
- Journal :
- Current pharmaceutical design
- Publication Type :
- Academic Journal
- Accession number :
- 20482507
- Full Text :
- https://doi.org/10.2174/138161210791516440